Paul Hastings Advised Goldman Sachs, J.P. Morgan, TD Cowen, and Stifel on Syndax Pharmaceuticals’ $200 Million Public Offering
Paul Hastings LLP advised Goldman Sachs & Co. LLC, J.P. Morgan, TD Cowen, and Stifel as the joint book running managers in connection with Syndax Pharmaceuticals’ (Nasdaq: SNDX) $200 million public offering of common stock. In addition, Syndax granted the underwriters a 30-day option to purchase up to an additional $30 million of shares. Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies.
Partner and co-head of Equity Capital Markets and co-chair of the Corporate Life Sciences Group Seo Salimi and Securities and Capital Markets partner Will Magioncalda led the Paul Hastings team, which also included associates Chris Guerin and Jorge Juan Ballen.
More details about the transaction can be found here.
With widely recognized elite teams across 18 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world's leading investment banks, asset managers and corporations.